Every 10-Q that Opko Health Inc. (OPK) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow OPK and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full OPK filings page.
OPKO Health, Inc. (OPK) filed an amended quarterly report primarily to correct CEO certification exhibits; the amendment does not change previously reported results. For the quarter ended June 30, 2026, OPKO generated $163.6 million in revenue, slightly above $156.8 million a year earlier, driven by higher product sales and a large increase in revenue from transfer of intellectual property and other, offset by lower service revenue. Total costs and expenses fell sharply, leading to an operating loss of $7.0 million versus $60.0 million in the prior-year quarter, and a net loss of $8.4 million versus $148.4 million; loss per share improved to $(0.01) from $(0.19).
For the first six months of 2026, revenue was $287.8 million, down from $306.8 million, while the net loss narrowed to $63.3 million from $216.1 million as interest expense and other non-operating losses declined. Net cash used in operating activities improved to $62.8 million from $118.0 million. Cash, cash equivalents and restricted cash totaled $314.4 million at June 30, 2026, with total assets of $1.83 billion and shareholders’ equity of $1.18 billion. Total debt was $349.1 million, including $246.9 million of senior secured royalty financing and $89.8 million of 2029 Convertible Notes. OPKO continued its stock repurchase program, buying an additional 9.8 million shares for about $13.2 million in the first half of 2026.
OPKO Health, Inc. (OPK) filed an amended Quarterly Report for the three months ended March 31, 2026, primarily to replace an incorrect Section 302 certification and add the Chief Executive Officer’s certification; all other disclosures remain unchanged. OPKO reported total revenues of $124.2 million, down from $150.0 million a year earlier, as service revenue declined while product and IP-related revenue were modestly higher. The company recorded an operating loss of $51.0 million and a net loss of $54.8 million, both improved versus the prior-year quarter’s losses of $67.2 million and $67.6 million, respectively.
Cash, cash equivalents and restricted cash totaled $355.6 million at March 31, 2026, with net cash used in operating activities of $19.3 million, an improvement from $34.6 million used in the prior-year period. Total assets were $1.86 billion and total liabilities $652.2 million, including $246.6 million of senior secured royalty financing and $87.3 million of 2029 Convertible Notes. Under its stock repurchase program, OPKO bought back 3.95 million shares in the quarter for about $4.8 million, bringing total repurchases to roughly $92.0 million since inception.
OPKO Health reported Q2 2026 total revenues of 163,580 (thousands), slightly above 156,807 (thousands) a year earlier. Service revenues declined, while product revenue and revenue from transfer of intellectual property and other increased.
Operating loss narrowed to 6,972 (thousands) from 59,981 (thousands), helped by lower service costs, reduced selling, general and administrative expenses and an 18,070 (thousands) gain on sale of assets. Net loss was 8,416 (thousands), or $0.01 per share, versus 148,441 (thousands), or $0.19, in Q2 2025.
For the first six months of 2026, net cash used in operating activities improved to 62,810 (thousands) from 117,974 (thousands). Cash, cash equivalents and restricted cash totaled 314,432 (thousands) at June 30, 2026. The company carries 246,854 (thousands) of senior secured royalty debt and 89,857 (thousands) of convertible notes, and has repurchased 9,835,105 shares for about $13.2 million under a $200.0 million buyback program. During Q2 2026 OPKO also received $18.4 million of earnout cash tied to the 2025 Labcorp oncology asset sale. Management highlights risks including continued losses, foreign exchange exposure, potential goodwill and IPR&D impairments, and an appealed foreign tax assessment of approximately $246 million that could be materially adverse if resolved unfavorably.
OPKO Health reported first‑quarter 2026 revenue of $124.2M, down from $150.0M a year earlier, as service revenue declined while product and intellectual property revenue grew modestly. Total costs and expenses fell to $175.2M, improving the operating loss to $51.0M from $67.2M.
Net loss narrowed to $54.8M, or $0.07 per share, compared with a $67.6M loss, or $0.10 per share, in the prior‑year quarter. Cash, cash equivalents and restricted cash were $355.6M at March 31, 2026, with net cash used in operating activities improving to $19.3M from $34.6M.
Total assets were $1.86B and total liabilities $652.2M, leaving shareholders’ equity of $1.20B. The company continued its repurchase program, buying 3.95M shares for about $4.8M in the quarter, and remains exposed to foreign exchange movements, with 32.7% of revenue in non‑U.S. currencies.
OPKO Health filed its Q3 2025 10‑Q, reporting a profitable quarter driven by an asset sale. Total revenue was $151.7 million versus $173.6 million a year ago, with services at $95.2 million, products at $37.7 million, and transfer of intellectual property and other at $18.7 million. Operating income rose to $48.1 million from $14.2 million, aided by a $101.6 million gain on the sale of BioReference’s oncology diagnostics business to Labcorp.
Net income was $21.6 million (basic EPS $0.03), compared to $24.9 million last year. For the nine months, revenue was $458.4 million and net loss was $194.4 million, reflecting higher interest expense and the absence of prior‑year gains. Cash, cash equivalents and current restricted cash were $415.2 million, with total assets of $2.00 billion and total liabilities of $690.0 million.
The Labcorp oncology transaction delivered $192.5 million in consideration, including $173.3 million in cash and $19.2 million in escrow, plus up to $32.5 million in contingent consideration. OPKO continued its repurchase program, buying 24.3 million shares year‑to‑date for approximately $33.5 million, bringing total program spend to about $73.8 million. As of October 17, 2025, 767,701,280 common shares were outstanding. The company disclosed a foreign tax assessment of approximately $246 million; it has recorded a $9.9 million accrual related to uncertain tax positions.